Faiza Yousaf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Faiza Yousaf has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Numan Awais
Department of Medicine, Shaheed Ziaur Rahman Medical College & Hospital, Bogura, Bangladesh
3 shared publications - Danyal Bakht
King Edward Medical University, Mayo Hospital, Lahore, Pakistan
2 shared publications - Fahad Saleem
Department of Medicine, Punjab Medical College, Allied Hospital, Faisalabad, Punjab, Pakistan
2 shared publications - Maaz Amir
Department of Medicine, King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan
2 shared publications - Syed Faqeer Hussain Bokhari
King Edward Medical University, Lahore, Pakistan
2 shared publications - Zarwa Rashid
King Edward Medical University, Mayo Hospital, Lahore, Pakistan
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5902-5911
Radiofrequency ablation combined with systemic therapy versus systemic therapy alone for unresectable colorectal liver metastases: a systematic review and meta-analysis
Background: Colorectal cancer liver metastases (CRLM) remain a major therapeutic challenge with limited curative options. Radiofrequency ablation (RFA) has emerged as a potential adjunct to systemic therapy, but its survival benefit remains uncertain. Methods: This systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, the Cochrane Library, ScienceDirect, and Embase were searched through 16 June 2025. Data were analyzed using RevMan version 5.4. Hazard ratios (HRs) were pooled for overall survival (OS) and progression-free survival (PFS), and risk ratios (RRs) were calculated for binary outcomes, each with 95% confidence intervals (CIs). Risk of bias was assessed using RoB 2 and ROBINS-I. Results: Out of 4625 records screened, three studies comprising 614 patients met the inclusion criteria. Pooled analysis demonstrated that RFA combined with systemic therapy significantly improved OS (HR = 0.46, 95% CI: 0.36–0.60, P < 0.001) and PFS (HR = 0.37, 95% CI: 0.20–0.67, P < 0.001) compared with systemic therapy alone. Secondary endpoints showed lower mortality (RR = 0.67, 95% CI: 0.59–0.76, P < 0.001) and reduced disease progression (RR = 0.92, 95% CI: 0.87–0.98, P = 0.005) in the RFA group. Conclusions: RFA combined with systemic therapy is associated with improved OS and PFS, with a trend toward reduced mortality and disease progression compared with systemic therapy alone among patients with unresectable colorectal liver metastases. These findings suggest a potential role for RFA in multimodal treatment; however, they should be interpreted cautiously given the limited and heterogeneous evidence base.
- 21 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5902-5911
Open AccessRadiofrequency ablation combined with systemic therapy versus systemic therapy alone for unresectable colorectal liver metastases: a systematic review and meta-analysis
Background: Colorectal cancer liver metastases (CRLM) remain a major therapeutic challenge with limited curative options. Radiofrequency ablation (RFA) has emerged as a potential adjunct to systemic therapy, but its survival benefit remains uncertain. Methods: This systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, the Cochrane Library, ScienceDirect, and Embase were searched through 16 June 2025. Data were analyzed using RevMan version 5.4. Hazard ratios (HRs) were pooled for overall survival (OS) and progression-free survival (PFS), and risk ratios (RRs) were calculated for binary outcomes, each with 95% confidence intervals (CIs). Risk of bias was assessed using RoB 2 and ROBINS-I. Results: Out of 4625 records screened, three studies comprising 614 patients met the inclusion criteria. Pooled analysis demonstrated that RFA combined with systemic therapy significantly improved OS (HR = 0.46, 95% CI: 0.36–0.60, P < 0.001) and PFS (HR = 0.37, 95% CI: 0.20–0.67, P < 0.001) compared with systemic therapy alone. Secondary endpoints showed lower mortality (RR = 0.67, 95% CI: 0.59–0.76, P < 0.001) and reduced disease progression (RR = 0.92, 95% CI: 0.87–0.98, P = 0.005) in the RFA group. Conclusions: RFA combined with systemic therapy is associated with improved OS and PFS, with a trend toward reduced mortality and disease progression compared with systemic therapy alone among patients with unresectable colorectal liver metastases. These findings suggest a potential role for RFA in multimodal treatment; however, they should be interpreted cautiously given the limited and heterogeneous evidence base.
- Open Access
- 24 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (30) , e49933
Role of antazoline in cardioversion of atrial fibrillation: A PRISMA-compliant systematic review and meta-analysis
Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Antazoline, a first-generation antihistamine with antiarrhythmic properties, has shown efficacy in the rapid conversion of recent-onset AF to sinus rhythm; however, direct comparative evidence against standard antiarrhythmic agents remains limited. This study aims to systematically evaluate the efficacy and safety of antazoline for pharmacological cardioversion of AF, in comparison with standard antiarrhythmic agents such as amiodarone and propafenone. Methods: The methodology of this systematic review and meta-analysis adhered to the preferred reporting items for systematic reviews and meta-analyses guidelines. A systematic search was conducted in ScienceDirect, Embase, PubMed, and Cochrane Library from inception to April 2025, including citation and reference screening. Statistical analyses were performed using R version 2025.05.0 + 496. Results: From 172 records, 5 studies comparing antazoline with propafenone (n = 5) or amiodarone (n = 3) for AF were included. For antazoline vs propafenone, conversion to sinus rhythm favored antazoline (risk ratio [RR] 1.13 [95% confidence interval (CI): 1.04–1.23], P = .017). No significant difference was observed in time to conversion (mean difference −10.98 [95% CI: −124.93–102.98], P = .436), bradycardia (RR 0.84 [95% CI: 0.35–2.03], P = .478), hypotension (RR 0.40 [95% CI: 0.14–1.12], P = .056), or other adverse events (RR 1.24 [95% CI: 0.01–247.13], P = .694). For antazoline vs amiodarone, conversion to sinus rhythm favored antazoline (RR 1.22 [95% CI: 1.08–1.36], P = .018, I 2 = 0%), with no significant differences in bradycardia (RR 1.36 [95% CI: 0–1072357.09], P = .823) or hypotension (RR 1.05 [95% CI: 0.04–26.16], P = .877). Conclusion: Antazoline might be more effective than propafenone and amiodarone in achieving sinus rhythm in AF, with no significant differences in safety outcomes.
- 24 July 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (30) , e49933
Open AccessRole of antazoline in cardioversion of atrial fibrillation: A PRISMA-compliant systematic review and meta-analysis
Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Antazoline, a first-generation antihistamine with antiarrhythmic properties, has shown efficacy in the rapid conversion of recent-onset AF to sinus rhythm; however, direct comparative evidence against standard antiarrhythmic agents remains limited. This study aims to systematically evaluate the efficacy and safety of antazoline for pharmacological cardioversion of AF, in comparison with standard antiarrhythmic agents such as amiodarone and propafenone. Methods: The methodology of this systematic review and meta-analysis adhered to the preferred reporting items for systematic reviews and meta-analyses guidelines. A systematic search was conducted in ScienceDirect, Embase, PubMed, and Cochrane Library from inception to April 2025, including citation and reference screening. Statistical analyses were performed using R version 2025.05.0 + 496. Results: From 172 records, 5 studies comparing antazoline with propafenone (n = 5) or amiodarone (n = 3) for AF were included. For antazoline vs propafenone, conversion to sinus rhythm favored antazoline (risk ratio [RR] 1.13 [95% confidence interval (CI): 1.04–1.23], P = .017). No significant difference was observed in time to conversion (mean difference −10.98 [95% CI: −124.93–102.98], P = .436), bradycardia (RR 0.84 [95% CI: 0.35–2.03], P = .478), hypotension (RR 0.40 [95% CI: 0.14–1.12], P = .056), or other adverse events (RR 1.24 [95% CI: 0.01–247.13], P = .694). For antazoline vs amiodarone, conversion to sinus rhythm favored antazoline (RR 1.22 [95% CI: 1.08–1.36], P = .018, I 2 = 0%), with no significant differences in bradycardia (RR 1.36 [95% CI: 0–1072357.09], P = .823) or hypotension (RR 1.05 [95% CI: 0.04–26.16], P = .877). Conclusion: Antazoline might be more effective than propafenone and amiodarone in achieving sinus rhythm in AF, with no significant differences in safety outcomes.
- Open Access
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8828-8833
Profound hematologic instability in consanguinity-associated familial hemophagocytic lymphohistiocytosis: a pediatric case report
Introduction and Background: Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, life-threatening systemic inflammatory disorder characterized by excessive immune activation. It is primarily caused by mutations affecting cytotoxic function in natural killer cells and cytotoxic T lymphocytes. Early diagnosis and treatment are crucial due to the condition’s rapid progression and high mortality without intervention. Case Presentation: In August 2023, a 3-year-old Asian male patient was admitted, exhibiting symptoms of high fever, jaundice, and hepatosplenomegaly. Initial investigations revealed pancytopenia, elevated ferritin, and bone marrow hemophagocytosis, leading to a diagnosis of FHL. Patient was referred to the oncology department and started on initial chemotherapy with vinblastine, prednisolone, and mercaptopurine and continuation chemotherapy therapy with vinblastine. In May 2024, the patient re-presented with febrile episodes, a productive cough, and pleural effusion, findings indicative of pneumonia. Laboratory findings revealed persistent hematological instability characterized by thrombocytopenia and leukopenia, with episodes of leukocytosis, alongside deranged liver function tests. Management included antibiotics and supportive care, highlighting recurrent hematologic instability and pleural involvement in FHL management. Clinical Discussion: In our patient’s case, cytopenias played a critical role, underscoring profound hematologic instability and immune system dysfunction characteristic of FHL. Hyperferritinemia, indicative of intense inflammation and immune activation, was notable. The involvement of pleura further emphasizes the systemic nature of FHL, necessitating aggressive treatment with antibiotics and antifungal agents. Current management strategies encompass chemotherapy, antibiotics, and comprehensive supportive care. Prognosis varies, highlighting the importance of early diagnosis and adherence to treatment. Conclusion: This case underscores the diagnostic challenges and therapeutic complexities in managing FHL, particularly in the context of consanguinity and genetic predisposition. Advances in genetic testing and treatment modalities are critical for improving outcomes and long-term prognosis in FHL. Continued research is essential to refine diagnostic criteria and therapeutic strategies for optimal patient care.
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8828-8833
Open AccessProfound hematologic instability in consanguinity-associated familial hemophagocytic lymphohistiocytosis: a pediatric case report
Introduction and Background: Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, life-threatening systemic inflammatory disorder characterized by excessive immune activation. It is primarily caused by mutations affecting cytotoxic function in natural killer cells and cytotoxic T lymphocytes. Early diagnosis and treatment are crucial due to the condition’s rapid progression and high mortality without intervention. Case Presentation: In August 2023, a 3-year-old Asian male patient was admitted, exhibiting symptoms of high fever, jaundice, and hepatosplenomegaly. Initial investigations revealed pancytopenia, elevated ferritin, and bone marrow hemophagocytosis, leading to a diagnosis of FHL. Patient was referred to the oncology department and started on initial chemotherapy with vinblastine, prednisolone, and mercaptopurine and continuation chemotherapy therapy with vinblastine. In May 2024, the patient re-presented with febrile episodes, a productive cough, and pleural effusion, findings indicative of pneumonia. Laboratory findings revealed persistent hematological instability characterized by thrombocytopenia and leukopenia, with episodes of leukocytosis, alongside deranged liver function tests. Management included antibiotics and supportive care, highlighting recurrent hematologic instability and pleural involvement in FHL management. Clinical Discussion: In our patient’s case, cytopenias played a critical role, underscoring profound hematologic instability and immune system dysfunction characteristic of FHL. Hyperferritinemia, indicative of intense inflammation and immune activation, was notable. The involvement of pleura further emphasizes the systemic nature of FHL, necessitating aggressive treatment with antibiotics and antifungal agents. Current management strategies encompass chemotherapy, antibiotics, and comprehensive supportive care. Prognosis varies, highlighting the importance of early diagnosis and adherence to treatment. Conclusion: This case underscores the diagnostic challenges and therapeutic complexities in managing FHL, particularly in the context of consanguinity and genetic predisposition. Advances in genetic testing and treatment modalities are critical for improving outcomes and long-term prognosis in FHL. Continued research is essential to refine diagnostic criteria and therapeutic strategies for optimal patient care.